Testing CT-P53 versus Ocrevus for relapsing MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsing-remitting multiple sclerosis (not the progressive forms).
- You have signs of recent MS activity (like recent relapses or new MRI findings).
- Your nervous system symptoms have been stable for at least 30 days before starting.
- Your disability score is between 0 and 6.0 on the EDSS scale.
- You can safely have MRI scans (no MRI contraindications and no major issues completing MRI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This trial tests an injectable medication called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis. The goal is to see if it is safe and how well it works to control the disease.
This trial tests a biosimilar drug that acts like Ocrevus to treat multiple sclerosis. It aims to help manage disease activity and slow progression, and may be an option if you have relapsing or progressive MS.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Hear when a new Relapsing-remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.